Development of thymoma without myasthenia gravis in a patient with radiographic axial spondyloarthritis treated with tumor necrosis factor-α inhibitors
Department of Life, Health and Environmental Sciences, University of L’Aquila; Internal Medicine and Nephrology Division, ASL1 Avezzano-Sulmona-L’Aquila, San Salvatore Hospital, L’Aquila
Francesco Maria Mariani
Department of Life, Health and Environmental Sciences, University of L’Aquila; Internal Medicine and Nephrology Division, ASL1 Avezzano-Sulmona-L’Aquila, San Salvatore Hospital, L’Aquila
Evy Di Ruscio
Department of Life, Health and Environmental Sciences, University of L’Aquila; Internal Medicine and Nephrology Division, ASL1 Avezzano-Sulmona-L’Aquila, San Salvatore Hospital, L’Aquila
Department of Life, Health and Environmental Sciences, University of L’Aquila; Internal Medicine and Nephrology Division, ASL1 Avezzano-Sulmona-L’Aquila, San Salvatore Hospital, L’Aquila
Department of Life, Health and Environmental Sciences, University of L’Aquila; Internal Medicine and Nephrology Division, ASL1 Avezzano-Sulmona-L’Aquila, San Salvatore Hospital, L’Aquila
Alessia Alunno
Department of Life, Health and Environmental Sciences, University of L’Aquila; Internal Medicine and Nephrology Division, ASL1 Avezzano-Sulmona-L’Aquila, San Salvatore Hospital, L’Aquila
Thymic tumors are rare in the general population, and to the best of our knowledge, no cases of thymoma have been described in patients with rheumatic diseases treated with tumor necrosis factor (TNF)-α inhibitors, except the case of a patient receiving infliximab for Crohn’s disease (CD) who developed a B2 thymoma. We describe a 60-year-old Caucasian male with radiographic axial spondyloarthritis (r-axSpA) and CD who developed an AB-type thymoma without myasthenia gravis after 18 years of treatment with TNF-α inhibitors. The patient had received the same molecule since the r-axSpA/CD diagnosis and changed it 6 months before the diagnosis of thymoma due to a disease flare. At the time of the drug switch, no mediastinal mass was present on the chest X-ray. The thymoma was surgically removed, and no additional therapy was needed. Treatment with TNF-α inhibitors was reintroduced after surgery. This case raises some important questions that remain open and deserve to be addressed in the future, such as the association between immunosuppressive therapy and thymoma and the controversial relationship between TNF-α inhibitors and myasthenia gravis.
